SEHK:9969Biotechs
InnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials
In July 2026, InnoCare Pharma reported that it had dosed the first patient in a Chinese clinical trial of ICP-B208, a novel in-house CDH17-targeted antibody-drug conjugate (ADC) designed with a proprietary payload and protease-cleavable linker for improved stability and safety.
This marks an early but important test of InnoCare’s ADC platform against CDH17, a tumor-restricted target relevant to multiple gastrointestinal cancers for which no CDH17 ADCs are yet approved globally.
Next, we’ll...